Showing results (61-70 of 105) with videos related to

Sort By:
Pageof 11
The Lancet. Haematology|November 26, 2021
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 studyCatherine Diefenbach, Brad S Kahl, Andrew McMillan, et al.
Annals of Hematology|May 6, 2020
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patientsEva González-Barca, Francisco Javier Capote, Jose Gómez-Codina, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 3, 2005
Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioningRodrigo Martino, José A Pérez-Simón, Estela Moreno, et al.
Haematologica|June 13, 2003
International and Italian prognostic indices in follicular lymphomaGranada Perea, Albert Altés, Silvia Montoto, et al.
Frontiers in Immunology|June 26, 2024
Optimization of a home hospitalization program for hematopoietic stem cell transplantation with ehealth integration and clinical pharmacist involvementMaria-Estela Moreno-Martinez, Mireia Riba, Irene García-Cadenas, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 19, 2018
Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to TherapyEva Puy Vicente, Carolina Cuellar-García, Montserrat Martinez, et al.
Transplantation and Cellular Therapy|April 22, 2023
Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the LiteratureIrene García-Cadenas, Sara Redondo, Albert Esquirol, et al.
Haematologica|October 16, 2012
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphomaVincent Ribrag, Dolores Caballero, Christophe Fermé, et al.
Haematologica|October 29, 2013
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trialJavier Briones, Silvana Novelli, José A García-Marco, et al.
European Journal of Haematology|February 11, 2021
Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivorsHugo Vachon, Justyna Mierzynska, Mekdes Taye, et al.
Pageof 11